Please login to the form below

Not currently logged in
Email:
Password:

Teva appoints genetics specialist as its first president of global R&D

Michael Hayden will also serve as chief scientific officer at the generics company

Michael Hayden - Teva PharmaceuticalTeva Pharmaceutical has appointed genetics expert Dr Michael Hayden as its first president of global R&D and chief scientific officer.

The move shows further research ambitions for the traditionally generics-focused company, with Dr Hayden to lead the development of both branded and generic medicines.

Dr Hayden's extensive background in genetics is likely to be important for Teva too, considering the industry's increasing interest in personalised medicines.

His experience in the field includes current roles as Killam Professor of Medical Genetics at the University of British Columbia, Canada, and Canada research chair in human genetics and molecular medicine as part of a government-supported programme.

He is also the founder and director of the centre for molecular medicine and therapeutics at the University of British Columbia.

In addition, Dr Hayden has experience within the biopharma industry, having founded the biotech companies NeuroVir, Aspreva Pharmaceuticals and Xenon Genetics.

Dr Jeremy Levin, who is set to replace Shlomo Yania as Teva's president and CEO, said: “We are delighted to have Michael join us as our chief scientific officer. He brings to Teva world-renowned experience and knowledge in scientific and clinical research coupled with deep knowledge of discovery and development of medicines.”

10th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics